Fifteen-year experience with natalizumab in the treatment of multiple sclerosis – a description of 15 clinical cases
Natalizumab, a humanized anti-α4-integrin antibody, is a valuable therapeutic option for relapsing-remitting multiple sclerosis and has been widely used in this indication since 2006. The growing body of data on its high efficacy and safety profile, both from randomised trials and clinical practice, has allowed to identify risk factors for progressive multifocal leukoencephalopathy and to develop a preventive algorithm, which increased the therapeutic safety. We present a description of 15 patients with relapsing-remitting multiple sclerosis treated with natalizumab in 15 different centres throughout Poland. The drug was included both due to first-line treatment failure and in cases of rapidly progressing, severe form of multiple sclerosis. The patients differed in terms of disease duration, the length of natalizumab therapy, and JCV serological status. The described cases include patients from the natalizumab registration trial, women who became pregnant while on the therapy, and patients who developed COVID-19. The presented case reports summarise the experience to date with the use of natalizumab in the treatment of relapsing-remitting multiple sclerosis in Poland.
Monika Buchajewicz, Justyna Chojdak-Łukasiewicz, Anna Pokryszko-Dragan, Anna Jamroz-Wiśniewska, Konrad Rejdak, Katarzyna Kapica-Topczewska, Anna Karbicka, Katarzyna Kubicka-Bączyk, Monika Adamczyk-Sowa, Monika Marona, Marcin Wnuk, Amira Bryll, Tadeusz Popiela, Agnieszka Słowik, Adam Perenc, Przemysław Puz, Natalia Szejko, Monika Nojszewska, Aleksandra Podlecka-Piętowska, Beata Zakrzewska-Pniewska, Elżbieta Tokarz-Kupczyk, Agata Walczak, Anna Wojnarowska-Arendt, Katarzyna Zaręba, Maciej Maciejowski, Marcin Zedler, Alina Kułakowska
Aktualn Neurol 2022, 22 (1), p. 39–59